Corbus Pharmaceuticals
CRBP
34 hedge funds and large institutions have $4.53M invested in Corbus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 1 closing their positions.
21,300% more call options, than puts
Call options by funds: $214K | Put options by funds: $1K
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
26% more funds holding
Funds holding: 27 → 34 (+7)
0.15% more ownership
Funds ownership: 16.81% → 16.96% (+0.15%)
10% less capital invested
Capital invested by funds: $5.01M → $4.53M (-$478K)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$112K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.39K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.17K |
| 4 |
Citigroup
New York
|
+$3.04K |
| 5 |
BL
BFSG LLC
Irvine,
California
|
+$327 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$67.3K |
| 2 |
Morgan Stanley
New York
|
-$6.61K |
| 3 |
JP Morgan Chase
New York
|
-$6.24K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.62K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.12K |
CRBP Hedge Fund Activity: Q4 2023 in Review
34 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2023, worth a combined $4.53M — down 9.6% from $5.01M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CRBP positions and 1 closed out — a net gain of 7 holders — while 3 added to existing stakes and 8 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $112K. The largest seller was Dimensional Fund Advisors, cutting an estimated $67.3K.
- 34 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2023, up from 27 in Q3 2023.
- Funds reported $4.53M of Corbus Pharmaceuticals stock for Q4 2023, down 9.6% quarter-over-quarter.
- 8 funds opened new Corbus Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +7 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2023 was Royal Bank of Canada, an estimated $112K added.
- The largest Corbus Pharmaceuticals seller in Q4 2023 was Dimensional Fund Advisors, an estimated $67.3K sold.
Based on aggregated 13F filings for Q4 2023.